PolandPoland

Early GM use holds large benefits

10.07.2005

Canterbury - Early adoption of GM technology in arable crops would bring clear farm level and environmental benefits for Poland according to a new report by Graham Brookes, of Brooks West, UK, and Prof. Andrzej Aniol, from the Polish Plant Breeding and Acclimatization Institute, published in the journal Biotechnologica.
The report shows that the application and use of the GM agronomic traits of herbicide tolerance to oilseed rape, sugar beet and maize, and insect (Bt) resistance in maize offers Poland both economic and environmental benefits.
The authors claim that Polish arable farmers have the potential to gain more from early adoption of GM technology than their EU 15 counterparts because they are starting from a lower average level of technical efficiency that enables Polish producers to compete more effectively, and earlier than they might otherwise have been capable of, if they did not use GM technology. Key findings forecast that adoption of GM technology would result in annual increases in output of between 10% and 19% for crops like oilseed rape (for export and as a raw material for bio-fuels) and sugar beet (for export without EU subsidy or for use in non-food sectors like bio-ethanol).
This represents an increase in farm (gross margin) income of between Euro67 million and Euro123 million. There will be greater opportunities to move to low tillage cultivation methods, which reduce soil disruption, erosion, and the release of carbon dioxide from ploughing and hence make a positive contribution to reducing the impact of global warming.

PolandPoland

09.05.2011

Krakow –Polish drug discovery company Selvita has entered into definitive agreements with investors in Poland to sell, in a private placement, 2.7 million shares of its stock at a price of PLN 5.5 per share, resulting in gross...

PolandPoland

06.04.2011

Krakow – Polish drug discovery specialist Selvita S.A. is to carry out virtual compound screening for a protein target provided by the Branford-based Institutes for Pharmaceutical Discovery (IPD) in the US. Selvita said the...

PolandPoland

04.04.2011

Warsaw – Poland’s policy concerning genetically modified organisms (GMOs) has been challenged by the European Commission. In mid-March, the Commission sued Poland at the European Court of Justice (ECJ) for establishing a ban on...

PolandPoland

25.02.2011

Szczecin/Greifswald – In Greifswald, the consensus in mid-March at the “Life Science for Health Economy – Chances and Challenges in Polish-German Cooperation” meeting was that the life sciences would benefit remarkably from...

PolandPoland

06.02.2011

Warsaw – Polish drugmaker Bioton S.A. and Iceland-based generics firm Actavis Group ptc announced in January that they are entering into a marketing and distribution collaboration agreement for Bioton’s insulins and insulin...

PolandPoland

04.11.2010

Warsaw – Merck, Sharp & Dome Polska is to expand its clinical research in the country. The company announced it is investing about US$ 50m in the creation of a data management centre where data from clinical trials conducted in...

PolandPoland

19.09.2010

Warsaw – Polish Agriculture Minister Marek Sawicki has sharply criticised the European Commission’s proposal to let EU member states decide on their own whether or not to plant genetically mod­i­fied crops. “This proposal is not...

PolandPoland

18.09.2010

Krakow – Polish drug developer Selvita sp. z o.o. and Finnish drug and diagnostic firm Orion Corporation (Espoo) have entered into a global collaboration to jointly develop and commercialise Selvita’s oral compound SEL103 as a...

PolandPoland

10.07.2010

Warsaw – While industrial biotechnology companies such as Royal DSM or Novozymes have welcomed new EU climate goals, believing they will provide a kickstart for a bio-based economy, eastern European countries like Bulgaria, the...

PolandPoland

09.07.2010

Kraków/ Espoo – Finland’s Orion Corp and Polish drugmaker Selvita have agreed to collaborate on research and development of Selvita’s oral Alzheimer compound SEL103 program in multiple cognitive disorder indications. According to...

Displaying results 11 to 20 out of 108

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-poland/browse/1/article/early-gm-use-holds-large-benefits.html

Product of the week

Products

Events

All Events

Current issue

All issues